Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

84. Ocrelizumab (Ocrevus Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis

Ocrelizumab (Ocrevus Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation HAYES, Inc. Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Multiple sclerosis (MS) is an autoimmune disorder that impacts the spinal cord and brain. MS presents in various forms, including relapsing-remitting MS (RRMS) or primary progressive MS (PPMS). Technology Description: Ocrelizumab (Ocrevus) is a humanized monoclonal antibody therapy

Health Technology Assessment (HTA) Database.2017

85. Fingolimod (Gilenya) - highly active relapsing remitting multiple sclerosis

Fingolimod (Gilenya) - highly active relapsing remitting multiple sclerosis Final Appraisal Recommendation Advice No: 3516 – December 2016 Fingolimod (Gilenya ® ) 0.5 mg hard capsules Submission by Novartis Pharmaceuticals UK Ltd Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3135), which (...) in full and cited as: All Wales Medicines Strategy Group Final Appraisal Recommendation – 3516: Fingolimod (Gilenya ® ) 0.5 mg hard capsules December 2016 Recommendation of AWMSG Fingolimod (Gilenya ® ) is recommended as an option for use within NHS Wales for use as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following adult patient group: - patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling

All Wales Medicines Strategy Group2017

86. Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate

Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate Article Text Commentary: General medicine Ocrelizumab

Evidence-Based Medicine (Requires free registration)2017

87. 29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report

29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report 28163856 2018 11 13 2008-5842 8 12 2016 Dec Electronic physician Electron Physician 29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report. 3409-3411 10.19082/3409 Multiple sclerosis (MS) is the most common debilitating neurological disease that affects adults, whether young adults or middle-aged. Although, most attention is toward the neurological signs of the disease, the neuropsychiatric signs (...) are not uncommon. This case report presents a 29 year old male with a record of obsessive-compulsive disorder (OCD) without psychotic disorder, which coincides with the diagnosis MS, has been stricken to auditory hallucinations and reference delusion. The patient received some antipsychotic drugs such as Haloperidol and Perphenazine irregularly, but any psychotic signs of the patient were never in control. During this period he had several active episodes of MS disease, wherein the symptoms had subsided due

Electronic physician2016 Full Text: Link to full Text with Trip Pro

88. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. BACKGROUND: B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. METHODS: In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 (...) ;0.001). The change in the Multiple Sclerosis Functional Composite score (a composite measure of walking speed, upper-limb movements, and cognition; for this z score, negative values indicate worsening and positive values indicate improvement) significantly favored ocrelizumab over interferon beta-1a in trial 2 (0.28 vs. 0.17, P=0.004) but not in trial 1 (0.21 vs. 0.17, P=0.33). Infusion-related reactions occurred in 34.3% of the patients treated with ocrelizumab. Serious infection occurred in 1.3

NEJM2016

89. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. BACKGROUND: An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease. METHODS: In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiple sclerosis in a 2:1 ratio (...) difference between groups in the rates of serious adverse events and serious infections. CONCLUSIONS: Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab. (Funded by F. Hoffmann-La Roche; ORATORIO ClinicalTrials.gov number, NCT01194570 .).

NEJM2016

90. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort

Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal (...) multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Health Technology Assessment 2016; 20(81) Authors' objectives The ability to better predict disease progression represents a major unmet need in multiple sclerosis (MS), and would help to inform therapeutic and management choices. This study aims to develop multilevel models using longitudinal data on disease progression in patients with relapsing–remitting MS (RRMS) or secondary

Health Technology Assessment (HTA) Database.2016

91. Diagnosis of multiple sclerosis: progress and challenges.

Diagnosis of multiple sclerosis: progress and challenges. The diagnosis of multiple sclerosis is based on neurological symptoms and signs, alongside evidence of dissemination of CNS lesions in space and time. MRI is often sufficient to confirm the diagnosis when characteristic lesions accompany a typical clinical syndrome, but in some patients, further supportive information is obtained from cerebrospinal fluid examination and neurophysiological testing. Differentiation is important from other (...) diseases in which demyelination is a feature (eg, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis) and from non-demyelinating disorders such as chronic small vessel disease and other inflammatory, granulomatous, infective, metabolic, and genetic causes that can mimic multiple sclerosis. Advances in MRI and serological and genetic testing have greatly increased accuracy in distinguishing multiple sclerosis from these disorders, but misdiagnosis can occur. In this Series

Lancet2016

92. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accumulation of disability that characterises progressive multiple sclerosis seems to result more from diffuse (...) immune mechanisms and neurodegeneration. As a result, the 14 anti-inflammatory drugs that have regulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no efficacy in progressive multiple sclerosis without inflammatory lesion activity. Effective therapies for progressive multiple sclerosis that prevent worsening, reverse damage, and restore function are a major unmet need. In this Series paper we summarise the current status of therapy for progressive

Lancet2016

93. Evolving concepts in the treatment of relapsing multiple sclerosis.

Evolving concepts in the treatment of relapsing multiple sclerosis. In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The increasing availability of effective disease-modifying therapies has shifted the aim of therapeutic interventions from a reduction in relapses and disability accrual, to the absence of any sign of clinical or MRI activity. The choice for therapy is increasingly complex and should be driven by an appropriate knowledge of the mechanisms

Lancet2016

95. Disease modifying therapies for relapsing multiple sclerosis.

Disease modifying therapies for relapsing multiple sclerosis. Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a secondary progressive phase. Inflammatory and neurodegenerative mechanisms seem to operate in both phases, but their relative contributions and interactions are incompletely understood. Disease modifying therapies (DMTs) approved for relapsing (...) multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials. Benefits of longer duration of therapy on disability are less clear, as data beyond three years are largely limited to observational studies. However, current DMTs do not slow accrual of disability once progressive

BMJ2016

96. Daclizumab (Zinbryta) - multiple sclerosis

Daclizumab (Zinbryta) - multiple sclerosis Zinbryta (daclizumab) Injection U.S. Department of Health and Human Services Search FDA Submit search Zinbryta (daclizumab) Injection Zinbryta Company: Biogen Inc. Application No.: 761029 Approval Date: 05/27/2016 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 7, 2016 Vision

FDA - Drug Approval Package2016

97. The Effectiveness of Group Cognitive Behavioral Therapy in Treating Obsessive-Compulsive Disorder in Women with Multiple Sclerosis (MS): A randomized double-blind controlled trial.

The Effectiveness of Group Cognitive Behavioral Therapy in Treating Obsessive-Compulsive Disorder in Women with Multiple Sclerosis (MS): A randomized double-blind controlled trial. 27279999 2016 06 09 2016 06 09 2017 02 20 8 4 2016 Apr Electronic physician Electron Physician The Effectiveness of Group Cognitive Behavioral Therapy in Treating Obsessive-Compulsive Disorder in Women with Multiple Sclerosis (MS): A randomized double-blind controlled trial. 2243-8 10.19082/2243 Obsessive (...) -compulsive disorder (OCD) is one of the most prevalent psychiatric disorders and can cause problems for individuals in all aspects of life, including social and personal dimensions. To study the effect of group cognitive-behavioral therapy on the reduction of OCD symptoms in female participants with multiple sclerosis (MS). This double-blind randomized control trial was conducted from May 2012 to December 2014. The participants included 75 patients with MS who suffered from OCD and were referred to the Loghman Hakim

Electronic physician2016 Full Text: Link to full Text with Trip Pro

98. Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines

Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness (...) and Guidelines Published on: May 4, 2016 Project Number: RB0983-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question 1. What is the clinical effectiveness of delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis? 2. What are the evidence-based guidelines associated with delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis? Key Message Three systematic

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

99. Modifiable Risk Factors in the Progression of Multiple Sclerosis

Modifiable Risk Factors in the Progression of Multiple Sclerosis Management Briefs Search the HSR&D website Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Brief no. 111 » Issue 111 April 2016 The systematic review reported on here is a product of the VA/HSR&D Quality Enhancement Research Initiative (QUERI) Evidence-Based Synthesis Program. Systematic (...) Review: Modifiable Risk Factors in the Progression of Multiple Sclerosis Multiple sclerosis (MS) is the most common progressive disease of the central nervous system in young adults and the cause of serious physical disability in adults of working age. MS disease presentation is very heterogeneous with variable clinical manifestations that evolve over time. In about 50 percent of patients the course of MS changes from relapsing-remitting to secondary progressive disease after ten years. Relapsing

Veterans Affairs - R&D2016

100. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis.

Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27074083 Format MeSH and Other (...) Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Apr 14;374(15):1495-6. doi: 10.1056/NEJMc1513302. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. 1 , 1 , 1 . 1 Yale School of Medicine, New Haven, CT kevin.oconnor@yale.edu. PMID: 27074083 PMCID: DOI: [Indexed for MEDLINE] Images from this publication. Figure 1 Detection of KIR4.1

NEJM2016 Full Text: Link to full Text with Trip Pro